Skip to main content
Paragen Bio banner
Paragen Bio logo

Paragen Bio

Paragen Bio is a provider of a technology intended to treat autoimmune diseases.

Backed by

AbbVie VenturesAbbVie Ventures
OneVenturesOneVentures
Brandon CapitalBrandon Capital

Raised 6M EQUITY on August 15, 2018

About

Paragen Bio develops therapeutics for autoimmune diseases using secretions from parasitic hookworms, based at James Cook University in Queensland.

Mission

Paragen Bio is a Queensland biotech startup developing treatments for autoimmune diseases by harnessing secretions from parasitic hookworms. The company is based at James Cook University. It launched with an initial $6 million investment to continue development of its therapeutics. Backers include US-based AbbVie Ventures and Australian venture capital firms OneVentures and Brandon Capital via the Medical Research Commercialisation Fund. OneVentures' investment is backed by the Australian government's Biomedical Translation Fund, a program focused on therapeutics and medical devices with clear commercial pathways or close to clinical development. Paragen intends to use the funding to continue developing its hookworm-secretions-based treatments for autoimmune conditions.

Quick Facts

Founded

2018

Funding

EQUITY

Industry

Biopharma, Biotechnology, Life Science

Team Size

11-50

Headquarters

Brisbane, Queensland, Australia

Paragen Bio | Matchbox | Matchbox